{"count":23932,"next":"http://api.gregory-ms.com/articles/?page=6","previous":"http://api.gregory-ms.com/articles/?page=4","results":[{"article_id":282420,"title":"Unveiling the Intricacies: A Comprehensive Review of Magnetic Resonance Imaging (MRI) Assessment of T2-Weighted Hyperintensities in the Neuroimaging Landscape","summary":"T2-weighted hyperintensities in neuroimaging represent areas of heightened signal intensity on magnetic resonance imaging (MRI) scans, holding crucial importance in neuroimaging. This comprehensive review explores the T2-weighted hyperintensities, providing insights into their definition, characteristics, clinical relevance, and underlying causes. It highlights the significance of these hyperintensities as sensitive markers for neurological disorders, including multiple sclerosis, vascular...","link":"https://pubmed.ncbi.nlm.nih.gov/38529430/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Springer Science and Business Media LLC","container_title":"Cureus","authors":[{"author_id":346430,"given_name":"Rishabh","family_name":"Dhabalia","ORCID":null,"country":null},{"author_id":346431,"given_name":"Shivali V","family_name":"Kashikar","ORCID":null,"country":null},{"author_id":346432,"given_name":"Pratap S","family_name":"Parihar","ORCID":null,"country":null},{"author_id":346433,"given_name":"Gaurav V","family_name":"Mishra","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:58.521706Z","noun_phrases":null,"doi":"10.7759/cureus.54808","access":"open","takeaways":"T2-weighted hyperintensities in neuroimaging represent areas of heightened signal intensity on MRI scans.","categories":[]},{"article_id":282419,"title":"HB-EGF and EGF infusion following CNS demyelination mitigates age-related decline in regeneration of oligodendrocytes from neural precursor cells originating in the ventricular-subventricular zone","summary":"AbstractIn multiple sclerosis (MS), chronic demyelination initiated by immune-mediated destruction of myelin, leads to axonal damage and neuronal cell death, resulting in a progressive decline in neurological function. The development of interventions that potentiate remyelination could hold promise as a novel treatment strategy for MS. To this end, our group has demonstrated that neural precursor cells (NPCs) residing in the ventricular-subventricular zone (V-SVZ) of the adult mouse brain contribute significantly to remyelination in response to central nervous system (CNS) demyelination and can regenerate myelin of normal thickness. However, aging takes its toll on the regenerative potential of NPCs and reduces their contribution to remyelination. In this study, we investigated how aging influences the contribution of NPCs to oligodendrogenesis during the remyelination process and whether the delivery of growth factors into the brains of aged mice could potentiate the oligodendrogenic potential of NPCs. To enable us to map the fate of NPCs in response to demyelination induced at different postnatal ages,Nestin-CreERT2;Rosa26-LSL-eYFPmice were gavaged with tamoxifen at either 8 weeks, 30 weeks or one year of age before being challenged with cuprizone for a period of six weeks. Using osmotic minipumps, we infused heparin-binding EGF-like growth factor (HB-EGF), and/or epidermal growth factor (EGF) into the cisterna magna for a period of two weeks beginning at the peak of cuprizone-induced demyelination (n=6-8 mice per group). Control mice received artificial cerebrospinal fluid (vehicle) alone. Mice were perfused six weeks after cuprizone withdrawal and the contribution of NPCs to oligodendrocyte regeneration in the corpus callosum was assessed. Our data reveal that although NPC-derived oligodendrocyte generation declined dramatically with age, this decline was partially reversed by growth factor infusion. Notably, co-infusion of EGF and HB-EGF increased oligodendrocyte regeneration twofold in some regions of the corpus callosum. Our results shed light on the beneficial effects of EGF and HB-EGF for increasing the contribution of NPCs to remyelination and indicate their therapeutic potential to combat the negative effects of aging upon remyelination efficacy.","link":"https://pubmed.ncbi.nlm.nih.gov/38529498/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Cold Spring Harbor Laboratory","container_title":"","authors":[{"author_id":346426,"given_name":"Kaveh","family_name":"Moradi","ORCID":null,"country":null},{"author_id":346427,"given_name":"Stanislaw","family_name":"Mitew","ORCID":null,"country":null},{"author_id":346428,"given_name":"Yao Lulu","family_name":"Xing","ORCID":"http://orcid.org/0000-0002-5564-4589","country":"US"},{"author_id":346429,"given_name":"Tobias D.","family_name":"Merson","ORCID":"http://orcid.org/0000-0002-7246-3608","country":"US"}],"relevant":true,"ml_prediction_gnb":false,"ml_prediction_lr":true,"ml_prediction_lsvc":true,"discovery_date":"2024-03-27T10:57:54.202941Z","noun_phrases":null,"doi":"10.1101/2024.02.26.582092","access":"open","takeaways":"In MS, chronic demyelination is initiated by immune-mediated destruction of myelin. Neuronal precursor cells (NPCs) residing in the ventricular-subventricular zone (V-SVZ) of the adult mouse brain can regenerate myelin of normal thickness. Aging takes its toll on the regenerative potential of NPCs. Infusion of EGF and HB-EGF increased oligodendrocyte regeneration in some regions of the corpus call","categories":[]},{"article_id":282418,"title":"Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study","summary":"ObjectiveAlthough off‐label use of rituximab is a common alternative to disease‐modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this on treatment cost‐effectiveness is not well known.MethodsWe evaluated the relative cost‐effectiveness of rituximab and MS‐approved DMTs in a register‐based cohort study of Swedish residents with relapsing–remitting MS, aged 18–65 years, starting treatment with rituximab, natalizumab, fingolimod, or dimethyl fumarate between January 2010 and July 2016, and followed through July 2021 (n = 5,924). By linking the population‐based Swedish MS register to several Swedish health care and demographic registers, we estimated health care costs in relation to number of relapses, over 5 years from treatment start. Differences between treatments were estimated in inverse probability of treatment‐weighted regression models, adjusting for a broad range of potential confounders covering demographics, medical history, and MS‐related clinical characteristics.ResultsOff‐label rituximab was associated with both lower total health care costs (mean cost savings ranged $35,000–$66,000 vs. each approved DMT), and fewer relapses (mean number of prevented relapses ranged 0.12–0.22), per started therapy over 5 years. Results were robust to variations in discounting and pricing of health care visits, with the main driver of cost‐savings being the price of the index drug itself.InterpretationThe cost‐effectiveness of rituximab dominated the MS‐approved alternatives. Off‐label, low‐dose rituximab should be considered for persons with MS and could reduce barriers to treatment, especially in resource‐limited settings. ANN NEUROL 2024","link":"https://pubmed.ncbi.nlm.nih.gov/38529711/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Wiley","container_title":"Annals of Neurology","authors":[{"author_id":315953,"given_name":"Peter","family_name":"Alping","ORCID":"http://orcid.org/0000-0002-4710-6326","country":"SE"},{"author_id":346425,"given_name":"Martin","family_name":"Neovius","ORCID":"http://orcid.org/0000-0003-2300-3055","country":null},{"author_id":157361,"given_name":"F.","family_name":"Piehl","ORCID":"http://orcid.org/0000-0001-8329-5219","country":null},{"author_id":222103,"given_name":"Thomas","family_name":"Frisell","ORCID":"http://orcid.org/0000-0002-5735-9626","country":"SE"}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:49.587756Z","noun_phrases":null,"doi":"10.1002/ana.26914","access":"open","takeaways":"Off-label use of rituximab is a common alternative to disease-modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries. The study of Swedish residents with relapsing-remitting MS, aged 18-65, followed from January 2010 to July 2016, and followed through July 2021, found that it is associated with lower health care costs and fewer relapses.","categories":[{"category_id":38,"category_description":"Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.","category_name":"Rituximab","category_slug":"rituximab","category_terms":["Rituximab","rituxan"],"article_count":118}]},{"article_id":282417,"title":"Infectious mononucleosis: new concepts in clinical presentation, epidemiology, and host response","summary":"\n Purpose of the review\n Infectious mononucleosis (IM) is an infectious disease that presents clinically in only a small percentage of individuals despite almost universal infection with the causative agent. Here, we review the latest concepts in the clinical presentation, epidemiology, and host response of this disease.\n \n \n Recent findings\n Several recently published papers/reviews describe IM as a condition caused by one of several etiologic agents including, cytomegalovirus (HHV-5), Roseola virus (HHV-6) and Toxoplasmosis amongst others; this review focuses on IM as solely caused by the human herpes virus 4 (HHV-4). Since the initial discovery of the virus in the 1960s and its subsequent discovery as the primary etiologic agent for IM it has been associated with several human cancers and autoimmune disorders. Recent published findings show a correlation between HHV-4 and the autoimmune disorder, multiple sclerosis (MS), suggesting earlier IM could possibly act as a causative factor. Considering the important links being made with IM to so many cancers and autoimmune disorders it is surprising that a standard investigative procedure has yet to be determined for this disease. A standard approach to the investigation of IM would ensure more cases are diagnosed, particularly atypical cases, this would benefit epidemiological studies, and more immediately help practitioners distinguish viral from bacterial throat infections, enabling them to treat accordingly.\n \n \n Summary\n The understanding of the latest concepts in clinical presentation, epidemiology and host response to IM would benefit greatly from the introduction of a standard procedure for its investigation and diagnosis.\n ","link":"https://pubmed.ncbi.nlm.nih.gov/38529804/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Ovid Technologies (Wolters Kluwer Health)","container_title":"Current Opinion in Infectious Diseases","authors":[{"author_id":346422,"given_name":"Patrick","family_name":"Naughton","ORCID":null,"country":null},{"author_id":346423,"given_name":"Frances","family_name":"Enright","ORCID":null,"country":null},{"author_id":346424,"given_name":"Brigid","family_name":"Lucey","ORCID":null,"country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:45.059002Z","noun_phrases":null,"doi":"10.1097/QCO.0000000000001012","access":"restricted","takeaways":"Infectious mononucleosis (IM) is an infectious disease that presents clinically in only a small percentage of individuals. IM is solely caused by the human herpes virus 4 (HHV-4). Since the initial discovery of the virus in the 1960s it has been associated with several human cancers and autoimmune disorders.","categories":[]},{"article_id":282416,"title":"The effectiveness of tele-rehabilitation for patients with multiple sclerosis during the COVID-19 pandemic in 2020—2021 was evaluated in this study","summary":"CONCLUSION: TeleRPT in patients can be an effective way to correct existing disorders. Further research is required to establish the effectiveness of teleRBT.","link":"https://pubmed.ncbi.nlm.nih.gov/38529866/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Media Sphere Publishing Group","container_title":"Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova","authors":[{"author_id":161121,"given_name":"S.A.","family_name":"Sivertseva","ORCID":"http://orcid.org/0000-0002-9293-5932","country":null},{"author_id":210926,"given_name":"K.S.","family_name":"Anfilofeva","ORCID":"http://orcid.org/0000-0002-0298-5128","country":null},{"author_id":210927,"given_name":"A.V.","family_name":"Zotova","ORCID":"http://orcid.org/0000-0003-1822-809X","country":null},{"author_id":346420,"given_name":"V.A.","family_name":"Kazantsev","ORCID":"http://orcid.org/0000-0003-0175-2733","country":null},{"author_id":346421,"given_name":"A.Yu.","family_name":"Belkina","ORCID":"http://orcid.org/0000-0001-9042-4664","country":null},{"author_id":322216,"given_name":"L.I.","family_name":"Volkova","ORCID":"http://orcid.org/0000-0002-2478-727X","country":null},{"author_id":210929,"given_name":"M.E.","family_name":"Guseva","ORCID":"http://orcid.org/0000-0002-3778-5206","country":null},{"author_id":147982,"given_name":"A.N.","family_name":"Boyko","ORCID":"http://orcid.org/0000-0002-2975-4151","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:40.563927Z","noun_phrases":null,"doi":"10.17116/jnevro202412403175","access":"restricted","takeaways":"","categories":[]},{"article_id":282415,"title":"REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program","summary":"CONCLUSIONS: Very high adherence rates independent of the PSP nursing service over 1 year of treatment indicate that IFN beta-1a sc is an easy-to-use and well-tolerated disease-modifying drug.","link":"https://pubmed.ncbi.nlm.nih.gov/38530606/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Springer Science and Business Media LLC","container_title":"Neurology and Therapy","authors":[{"author_id":288640,"given_name":"Matthias","family_name":"Schwab","ORCID":null,"country":null},{"author_id":151297,"given_name":"Andrew","family_name":"Chan","ORCID":"http://orcid.org/0000-0003-3434-7283","country":null},{"author_id":346418,"given_name":"Anna-Katharina","family_name":"Eser","ORCID":null,"country":null},{"author_id":265297,"given_name":"Boris","family_name":"Kallmann","ORCID":null,"country":null},{"author_id":262534,"given_name":"Dieter","family_name":"Pöhlau","ORCID":null,"country":null},{"author_id":291880,"given_name":"Joachim","family_name":"Richter","ORCID":null,"country":null},{"author_id":346419,"given_name":"Torsten B.","family_name":"Wagner","ORCID":null,"country":null},{"author_id":160584,"given_name":"Christoph","family_name":"Grothe","ORCID":"http://orcid.org/0000-0001-6817-6692","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:35.987746Z","noun_phrases":null,"doi":"10.1007/s40120-024-00593-x","access":"open","takeaways":"","categories":[]},{"article_id":282414,"title":"Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16)","summary":"Abstract\n Background\n The FROM-16 is a generic family quality of life (QoL) instrument that measures the QoL impact of patients’ disease on their family members/partners. The study aimed to assess the responsiveness of FROM-16 to change and determine Minimal Important Change (MIC).\n \n Methods\n Responsiveness and MIC for FROM-16 were assessed prospectively with patients and their family members recruited from outpatient departments of the University Hospital Wales and University Hospital Llandough, Cardiff, United Kingdom. Patients completed the EQ-5D-3L and a global severity question (GSQ) online at baseline and at 3-month follow-up. Family members completed FROM-16 at baseline and a Global Rating of Change (GRC) in addition to FROM-16 at follow-up. Responsiveness was assessed using the distribution-based (effect size-ES, standardized response mean -SRM) and anchor-based (area under the receiver operating characteristics curve ROC-AUC) approaches and by testing hypotheses on expected correlation strength between FROM-16 change score and patient assessment tools (GSQ and EQ-5D). Cohen’s criteria were used for assessing ES. The AUC ≥ 0.7 was considered a good measure of responsiveness. MIC was calculated using anchor-based (ROC analysis and adjusted predictive modelling) and distribution methods based on standard deviation (SD) and standard error of the measurement (SEM).\n \n Results\n Eighty-three patients with 15 different health conditions and their relatives completed baseline and follow-up questionnaires and were included in the responsiveness analysis. The mean FROM-16 change over 3 months = 1.43 (SD = 4.98). The mean patient EQ-5D change over 3 months = −0.059 (SD = 0.14). The responsiveness analysis showed that the FROM-16 was responsive to change (ES = 0.2, SRM = 0.3; p < 0.01). The ES and SRM of FROM-16 change score ranged from small (ES = 0.2; SRM = 0.3) for the distribution-based method to large (ES = 0.8, SRM = 0.85) for anchor-based methods. The AUC value was above 0.7, indicating good responsiveness. There was a significant positive correlation between the FROM-16 change scores and the patient’s disease severity change scores (p < 0.001). The MIC analysis was based on data from 100 family members of 100 patients. The MIC value of 4 was suggested for FROM-16.\n \n Conclusions\n The results of this study confirm the longitudinal validity of FROM-16 which refers to the degree to which an instrument is able to measure change in the construct to be measured. The results yield a MIC value of 4 for FROM-16. These psychometric attributes of the FROM-16 instrument are useful in both clinical research as well as clinical practice.\n ","link":"https://pubmed.ncbi.nlm.nih.gov/38530614/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Springer Science and Business Media LLC","container_title":"Journal of Patient-Reported Outcomes","authors":[{"author_id":196649,"given_name":"R.","family_name":"Shah","ORCID":"http://orcid.org/0000-0001-8158-712X","country":"GB"},{"author_id":196650,"given_name":"A. Y.","family_name":"Finlay","ORCID":"http://orcid.org/0000-0003-2143-1646","country":"GB"},{"author_id":196651,"given_name":"M. S.","family_name":"Salek","ORCID":"http://orcid.org/0000-0002-4612-5699","country":null},{"author_id":346415,"given_name":"H.","family_name":"Allen","ORCID":null,"country":null},{"author_id":346416,"given_name":"S.J.","family_name":"Nixon","ORCID":null,"country":null},{"author_id":346417,"given_name":"M.","family_name":"Nixon","ORCID":null,"country":null},{"author_id":196653,"given_name":"K.","family_name":"Otwombe","ORCID":"http://orcid.org/0000-0002-7433-4383","country":null},{"author_id":196654,"given_name":"F. M.","family_name":"Ali","ORCID":"http://orcid.org/0000-0002-4184-2023","country":"GB"},{"author_id":196655,"given_name":"J. R.","family_name":"Ingram","ORCID":"http://orcid.org/0000-0002-5257-1142","country":null}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:31.280025Z","noun_phrases":null,"doi":"10.1186/s41687-024-00703-1","access":"open","takeaways":null,"categories":[]},{"article_id":282413,"title":"Twin study dissects CXCR3+ memory B cells as non-heritable feature in multiple sclerosis","summary":"CONCLUSIONS: Circulating CXCR3^(+) memory B cells are affected by non-heritable cues in people who develop MS. This underlines the requirement of environmental risk factors such as Epstein-Barr virus in triggering these B cells. We propose that after CXCL10-mediated entry into the CNS, CXCR3^(+) memory B cells mature into antibody-secreting cells to drive MS.","link":"https://pubmed.ncbi.nlm.nih.gov/38531361/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Elsevier BV","container_title":"Med","authors":[{"author_id":262582,"given_name":"Florian","family_name":"Ingelfinger","ORCID":null,"country":null},{"author_id":309526,"given_name":"Kirsten L.","family_name":"Kuiper","ORCID":null,"country":null},{"author_id":346413,"given_name":"Can","family_name":"Ulutekin","ORCID":null,"country":null},{"author_id":346414,"given_name":"Lukas","family_name":"Rindlisbacher","ORCID":null,"country":null},{"author_id":172897,"given_name":"Sarah","family_name":"Mundt","ORCID":"http://orcid.org/0000-0003-2169-2109","country":"CH"},{"author_id":226933,"given_name":"Lisa Ann","family_name":"Gerdes","ORCID":"http://orcid.org/0000-0002-7053-3924","country":null},{"author_id":165580,"given_name":"Joost","family_name":"Smolders","ORCID":"http://orcid.org/0000-0001-9766-8661","country":"NL"},{"author_id":193988,"given_name":"Marvin M.","family_name":"van Luijn","ORCID":"http://orcid.org/0000-0002-1283-1018","country":null},{"author_id":172899,"given_name":"Burkhard","family_name":"Becher","ORCID":"http://orcid.org/0000-0002-1541-7867","country":"CH"}],"relevant":null,"ml_prediction_gnb":false,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:26.561588Z","noun_phrases":null,"doi":"10.1016/j.medj.2024.02.013","access":"open","takeaways":"CXCR3+ memory B cells are affected by non-heritable cues in people who develop MS","categories":[]},{"article_id":282412,"title":"Extended interval dosing of natalizumab: More evidence in support","summary":"No abstract","link":"https://pubmed.ncbi.nlm.nih.gov/38531713/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-26T10:00:00Z","source":"PubMed","publisher":"Elsevier BV","container_title":"Neurotherapeutics","authors":[{"author_id":206984,"given_name":"Karlo","family_name":"Toljan","ORCID":"http://orcid.org/0000-0002-3189-9659","country":null},{"author_id":256962,"given_name":"Devon S.","family_name":"Conway","ORCID":null,"country":null}],"relevant":false,"ml_prediction_gnb":true,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:21.917783Z","noun_phrases":null,"doi":"10.1016/j.neurot.2024.e00351","access":"open","takeaways":null,"categories":[{"category_id":7,"category_description":"","category_name":"Natalizumab","category_slug":"natalizumab","category_terms":["natalizumab","tysabri"],"article_count":295}]},{"article_id":282411,"title":"Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score","summary":"CONCLUSIONS: The EUMUS score is a simple and useful tool for predicting MS evolution within 12 months of the first clinical episode. It has the potential to guide personalized therapeutic approaches and aid in clinical decision-making.","link":"https://pubmed.ncbi.nlm.nih.gov/38532143/?fc=20210216052009&ff=20240327065651&v=2.18.0.post9+e462414","published_date":"2024-03-27T10:00:00Z","source":"PubMed","publisher":"Springer Science and Business Media LLC","container_title":"Journal of Neurology","authors":[{"author_id":158738,"given_name":"Giulia","family_name":"Mallucci","ORCID":"http://orcid.org/0000-0002-0031-9594","country":null},{"author_id":346412,"given_name":"Ottavia Eleonora","family_name":"Ferraro","ORCID":"http://orcid.org/0000-0002-4398-4885","country":"IT"},{"author_id":152739,"given_name":"Maria","family_name":"Trojano","ORCID":"http://orcid.org/0000-0002-6329-8946","country":null},{"author_id":147708,"given_name":"Maria Pia","family_name":"Amato","ORCID":"http://orcid.org/0000-0003-3325-3760","country":"IT"},{"author_id":164225,"given_name":"Antonio","family_name":"Scalfari","ORCID":"http://orcid.org/0000-0002-7757-0293","country":null},{"author_id":177080,"given_name":"Mauro","family_name":"Zaffaroni","ORCID":"http://orcid.org/0000-0001-9020-934X","country":null},{"author_id":222746,"given_name":"Elena","family_name":"Colombo","ORCID":"http://orcid.org/0000-0002-5265-5055","country":null},{"author_id":222747,"given_name":"Eleonora","family_name":"Rigoni","ORCID":"http://orcid.org/0000-0001-9669-0234","country":null},{"author_id":147222,"given_name":"Pietro","family_name":"Iaffaldano","ORCID":"http://orcid.org/0000-0003-2308-1731","country":null},{"author_id":147707,"given_name":"Emilio","family_name":"Portaccio","ORCID":"http://orcid.org/0000-0002-9662-1762","country":null},{"author_id":181829,"given_name":"Lorenzo","family_name":"Saraceno","ORCID":"http://orcid.org/0000-0002-0794-8406","country":null},{"author_id":177082,"given_name":"Damiano","family_name":"Paolicelli","ORCID":"http://orcid.org/0000-0002-8645-1763","country":"IT"},{"author_id":245381,"given_name":"Lorenzo","family_name":"Razzolini","ORCID":null,"country":null},{"author_id":158742,"given_name":"Cristina","family_name":"Montomoli","ORCID":"http://orcid.org/0000-0002-8526-5846","country":null},{"author_id":158743,"given_name":"Roberto","family_name":"Bergamaschi","ORCID":"http://orcid.org/0000-0002-1397-511X","country":null}],"relevant":false,"ml_prediction_gnb":true,"ml_prediction_lr":false,"ml_prediction_lsvc":false,"discovery_date":"2024-03-27T10:57:16.774719Z","noun_phrases":null,"doi":"10.1007/s00415-024-12304-5","access":"restricted","takeaways":"","categories":[]}]}